Cardio Diagnostics Holdings, Inc.

NasdaqCM CDIO

Cardio Diagnostics Holdings, Inc. Price to Book Ratio (P/B) on January 14, 2025

Cardio Diagnostics Holdings, Inc. Price to Book Ratio (P/B) is NA on January 14, 2025, a NA change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Cardio Diagnostics Holdings, Inc. 52-week high Price to Book Ratio (P/B) is NA on January 14, 2025, which is NA below the current Price to Book Ratio (P/B).
Cardio Diagnostics Holdings, Inc. 52-week low Price to Book Ratio (P/B) is NA on January 14, 2025, which is NA below the current Price to Book Ratio (P/B).
Cardio Diagnostics Holdings, Inc. average Price to Book Ratio (P/B) for the last 52 weeks is NA.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

NasdaqCM: CDIO

Cardio Diagnostics Holdings, Inc.

CEO	Dr. Meeshanthini V. Dogan Ph.D.
IPO Date	Jan. 14, 2022
Location	United States
Headquarters	400 N Aberdeen St
Employees	7
Sector	Health Care
Industries Clinical Trials Biotechnology

Description

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois.

Key trends

Past 5 years